Cargando…
Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase
BACKGROUND: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), is considered a risk factor for the pathogenesis of cardiovascular diseases. Simvastatin, a lipid‐lowering drug with other pleiotropic effects, has been widely used for treatment of c...
Autores principales: | Hsu, Chiao‐Po, Zhao, Jin‐Feng, Lin, Shing‐Jong, Shyue, Song‐Kun, Guo, Bei‐Chia, Lu, Tse‐Min, Lee, Tzong‐Shyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843600/ https://www.ncbi.nlm.nih.gov/pubmed/27091343 http://dx.doi.org/10.1161/JAHA.116.003327 |
Ejemplares similares
-
Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/dimethylarginine dimethylaminotransferase 2 pathway
por: Lee, Tzong-Shyuan, et al.
Publicado: (2021) -
The prognostic value of asymmetric dimethylarginine in patients with cardiac syndrome X
por: Lu, Tse-Min, et al.
Publicado: (2017) -
Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase
por: Hou, Hsin-Han, et al.
Publicado: (2015) -
Corrigendum: Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase
por: Hou, Hsin-Han, et al.
Publicado: (2017) -
Asymmetric Dimethylarginine, Endothelial Nitric Oxide Bioavailability and Mortality in Sepsis
por: Davis, Joshua S., et al.
Publicado: (2011)